Abstract
Objective
The aim of this study was to measure the impact of hospitalisation on hypnotic and anxiolytic (HA) drug prescription, during and after hospitalisation.
Method
A descriptive study was carried out over three periods: before, during and after hospitalisation (three-month follow-up), examining the presence or absence of HA treatment at each stage. The HA drug list studied was selected using the World Health Organisation (WHO) Anatomical Therapeutic and Chemical (ATC) classification system. Trained final-year pharmacy students asked a series of structured questions during hospitalisation and postal questionnaires were sent to included patients one and three months after discharge. All the in-patient departments in the University Hospital of Besançon—France—were included, except units with pre-, peri-, and post-operative HA treatments. All in-patients present in the selected units on February 12, 2003, aged over 18, who gave their consent and were considered able to answer by the nursing team, were finally included.
Main outcome measure
An eight-branch descriptive model, including the three study periods with two states (presence or absence of HA treatment) at each stage.
Results
A total of 260 in-patients were included, and a further 112 (43%) completed the whole study (alive, non re-hospitalised, one- and three- months post discharge response). 48% (n = 260), 64% (n = 260) and 58% (n = 112) of the included patients had sleep disorder complaints respectively before, during and after hospitalisation. HA usage increased when comparing pre- and during hospitalisation (33% vs. 51%; n = 112; p < 0.0001) and decreased when comparing during hospitalisation and post-discharge (51% vs. 43%; n = 112; p < 0.0001). The descriptive model showed an overall persistence of treatment induced by hospital stay in 5.35% of the patients.
Conclusion
Hospital appeared to have a significant impact on delayed HA use in the French general population. Our results should incite hospital prescribers to transversally reconsider the whole sleep disorder treatment strategy in hospital settings, from improving patient’s accommodation conditions, to working out a consensus on the justification of prescription of HA and precising the exact place of nursing team in sleep disorders management.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11096-007-9097-z/MediaObjects/11096_2007_9097_Fig1_HTML.gif)
Similar content being viewed by others
References
Zarifian E. Rapport: mission générale concernant la prescription et l’utilisation des médicaments psychotropes en France. Paris: La documentation Française; 1996.
Pelissolo A, Boyer P, Lepine JP, Bisserbe JC. Epidémiologie du recours aux médicaments anxiolytiques et hypnotiques en France et dans le monde [Epidemiology of the use of anxiolytic and hypnotic drugs in France and in the world]. Encéphale 1996;22(3):187–96.
Lecomte T, Paris V. Consommation pharmaceutique en 1988 [Pharmaceutical consumption in 1988]. Bul CREDES 1991;881:116–7.
Caisse Nationale d’Assurance Maladie des Travailleurs Salariés MEDIC’Assurance Maladie. Les médicaments remboursés par le régime Général d’Assurance Maladie au cours des années 2000 et 2001. Paris: CNAMTS; 2002.
France. Ministère de la Santé et de l’action humanitaire. Arrêté du 7 Octobre 1991 fixant la liste des substances vénéneuses à propriété hypnotique et/ou anxiolytique dont la durée de prescription est réduite (modifié par les arrêtés du 28/01/1992, 18/08/1992, 03/09/1992, 01/02/2001, 21/12/01). J Off Repub. Arrêtés 2001; (n°01-24440):321.
Ohayon M, Caulet M, Lemoine P. Patients âgés, habitudes de sommeil et utilisation de psychotropes dans la population française [The elderly, sleep habits and use of psychotropic drugs by the French population]. Encéphale 1996;22(5):337–50.
Zarifian E. Le prix du bien-être—psychotropes et société [The price of the wellbeing—psychotropic and society]. Paris: Editions Odile Jacob; 1996, ISBN 27-381-0405-3.
Edwards C, Bushnell JL, Ashton CH, Rawlins MD. Hospital prescribing and usage of hypnotics and anxiolytics. Br J Clin Pharmacol 1991;31(2):190–2.
Picone DA, D’Mello DA, Foote ML, Msibi B. A review of the utilisation of sedative-hypnotic drugs in a general hospital. Gen Hosp Psychiatry 1993;15(1):51–4.
Feely J, Chan R, McManus J, O’Shea B. The influence of hospital based prescribers on prescribing in general practice. Pharmacoeconomics 1999;16(2):175–81.
Riviere F, Bonnin M, Saux MC, Hazane C. L’hôpital est-il inducteur de la consommation d’hypnotiques? [Does hospitalisation induce hypnotic drug prescription?] Rev ADPHSO 1987;12(3):51–7.
Savoy J, Fauchere PA, Ferrero F. La prescription des psychotropes dans un hôpital général [Prescription of psychotropic drugs in a general hospital]. Med Hyg 1997;55:1704–5.
Ancoli-Israel S. Sleep problems in older adults: putting myths to bed. Geriatrics 1997;52(1):20–10.
Epstein DR, Bootzin RR. Insomnia. Nurs Clin North Am 2002;37(4):611–31.
Shaver JL. Women and sleep. Nurs Clin North Am 2002;37(4):707–1.
Maling TJ, Moon PA. Hypnotic drug prescribing and consumption in a New Zeland teaching hospital. N Z Med J 1983;96(740):730–3.
Villani P, Morciano C, Ambrosi P, Brondino-Riquier R, Bertault-Peres P, Penot-Ragon C, Bouvenot G. Prescriptions et consommations de médicaments hypnotiques et anxiolytiques au CHU-Sud de Marseille [Prescriptions and consumption of hypnotic and anxiolytic drugs in the South University Hospital of Marseille]. Thérapie 2001;56(1):11–4.
Empereur F, Baumann M, Alla F, Briancon S. Factors associated with the consumption of psychotropic drugs in a cohort of men and women aged 50 and over. J Clin Pharm Ther 2003;28(1):61–8.
Ohayon M, Lemoine P. Relations entre l’insomnie et les autres pathologies psychiatriques dans la population française [A connection between insomnia and psychiatric disorders in the French general population]. Encephale 2002;28(5pt1):420–8.
Leger D, Allaert FA, Massuel MA. La perception de l’insomnie en médecine générale. Enquête auprès de 6 043 médecins généralistes. [Attitudes about insomnia and its effect on daytime functioning. Survey of 6043 French general practitioners]. Presse Med 2005;34(19 Pt 1):1358–62.
Ohayon MM, Lemoine P. Répercussions diurnes de l’insomnie dans la population générale française [Daytime consequences of insomnia complaints in the French general population. Encéphale 2004;30(3):222–7.
Neubauer D. Pharmacologic approaches for the treatment of chronic insomnia. Clin Cornerstone 2003;5(3):16–27.
Dement WC, Pelayo R. Public health impact and treatment of insomnia. Eur Psychiatry 1997;12(suppl1):31s–38s.
Carey DL, Day RO, Cairns DR, Pearce GA, Wodak AD, Lauchlan RL. An attempt to influence hypnotic and sedative drug use. Med J Aust 1992;156(6):389–4.
Acknowledgments and public financial support
Conflicts of Interest This study has been carried out in the regional framework of «Projet Hospitalier de Recherche Clinique 2001». There is no potential conflict of interest that might be relevant to the content of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fagnoni, P., Limat, S., Haffen, E. et al. Does hospitalisation affect hypnotic and anxiolytic drug prescribing?. Pharm World Sci 29, 611–618 (2007). https://doi.org/10.1007/s11096-007-9097-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-007-9097-z